NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today that its CombiMatrix group’s subsidiary, Combimatrix Molecular Diagnostics (CMDX), has completed the clinical validation of and has launched the third version of its Constitutional Array Genetic Test (CA1000). The test utilizes the company’s Bacterial Artificial Chromosome (BAC) array, which includes over 200 new, validated probes obtained through the company’s partnerships with The Center of Applied Genomics (TCAG), in Toronto, Canada and the Erasmus University Medical Center, the Netherlands’ largest academic medical center.
